Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirepemat for Falls Frequency in Parkinson's Disease
NCT05258071Phase 2Completed
- Sponsor
- IRLAB
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of Pirepemat in Parkinson's disease (PD), sponsored by IRLAB. Started Jun 2022; status: completed.
02
Drugs
Pirepemat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05258071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258071.